G03BA03 testosterone

GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ANDROGENS 3-oxoandrosten (4) derivatives

健保收載品項 TFDA 在效許可證 15 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 15 張;以下列出 13 個品項。

健保收載品名:"台裕" 丙醯睪丸素注射液、"台裕"持效睪丸素注射液、"應元" 長效睪丸素注射液、"濟生"長效男士蒙注射液、得保偉雄、得保偉雄注射液200公絲、得斯多注射液、持續性得適多蒙注射液(持效睪丸素)、持續性敵世力猛注射液、持續性荷爾蒙-M針、持續性蓋世維雄注射液250公絲、持續性蓋世達蒙注射液200公絲、特補鐵士得朗針、男士蒙注射液、男性得補注射液、男性維保荷爾蒙注射液

無外觀照
得斯多注射液
無外觀照
荷爾蒙-M針25公絲
無外觀照
持續性荷爾蒙-M針
無外觀照
"台裕"持效睪丸素注射液
無外觀照
"台裕" 丙醯睪丸素注射液
無外觀照
長力大雄注射劑
無外觀照
"應元" 長效睪丸素注射液
無外觀照
昂斯妥凝膠
無外觀照
耐必多注射劑
無外觀照
耐他妥 鼻內凝膠劑
無外觀照
昂斯妥凝膠16.2毫克/公克
無外觀照
"大豐"得士蒙得保注射液
無外觀照
偉樂凝膠 1.62%

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 1.經臨床徵象及實驗室檢驗確認因睪固酮缺乏之男性生殖腺功能不足症(hypogonadism)的替代治療。2.月經過多血崩症、女性機能性經痛、抑乳及乳漲抑制、停經前後之乳癌、慢性乳炎、慢性子宮內膜炎。
  2. 經臨床徵象及實驗室檢驗確認因睪固酮缺乏之男性生殖腺功能不足症(hypogonadism)的替代治療。女性乳汁分泌之抑制、機能性子宮出血、月經困難、子宮內膜症、乳癌。
  3. 先天性睪丸發育不完全、更年期障礙、前列腺肥大症、性腺機能減退、經臨床徵象及實驗室檢驗確認因睪固酮缺乏之男性生殖腺功能不足症(hypogonadism)的替代治療。
  4. 男性荷爾蒙缺乏所致之諸症:腰酸背痛、攝護腺肥大、性能減退、乳汁分泌之抑制、更年期障礙。
  5. 男性更年期症狀(精力減退、肩酸、腰痛)性器官發育不健全、女性乳癌、慢性子宮內膜炎。
  6. 男性荷爾蒙不足引起之症狀等、更年期諸症狀之緩解(頭痛、倦怠、精力減退等)。
  7. 適合在成年男性中作為睪固酮補充療法、經臨床徵象及實驗室檢驗確認因睪固酮缺乏之男性生殖腺功能不足症(hypogonadism)的替代治療。
  8. 性腺機能減退、男子更年期障礙。
  9. 經臨床徵象及實驗室檢驗確認因睪固酮缺乏之男性生殖腺功能不足症(HYPOGONADISM)的替代治療。
  10. 男性更年期障礙。
  11. 男性激素缺乏症。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 testosterone (商品名 Female Stimulant / Hormone Harmony / Prostate / Testopel / Testosterone) · 仿單更新 2026-02-19

1 INDICATIONS AND USAGE Testosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )] . Testosterone gel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired) ( 1 ) Limitations of use: Safety and efficacy of testosterone gel 1.62% in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of testosterone gel 1.62% in males less than 18 years old have not been established. ( 1 , 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. ( 1 , 12.3 )

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。